Quorex Pharmaceuticals Inc.

Quorex Pharmaceuticals has discovered a regulatory molecule and signaling pathway that permits bacterial cells to sense when they have achieved the population density (a quorum) needed to initiate the successful infection of a host. It is developing compounds that disrupt that communication system, which is found in a range of pathogens, to prevent infection.

Quorum sensing, or the control of gene expression in response to cell density, is used by a wide variety of bacteria—both Gram-negative and Gram-positive—to regulate physiological functions, including signaling the onset of pathogenesis in a host and the acquisition of nutrients. Signaling molecules called autoinducers, which are produced by bacteria and accumulate in the external environment as the bacterial cells grow, enable this communication system. When a bacterial population achieves a threshold density—a quorum—the concentration of autoinducers reaches a certain concentration and triggers a signal transduction cascade in the bacteria. Quorum sensing was first discovered in the early 1980s when researchers found that the accumulation of a certain chemical autoinducers triggered bioluminescence in the marine bacterium, Vibrio fisherii. Similar autoinducers later were found to induce the expression of virulence factors in the Gram-negative pathogen, Pseudomonas aeruginosa. In Gram-positive bacteria, such as Staph aureus, a separate quorum mechanism triggers virulence via a peptide autoinducer molecule.

But these initial observations were species specific—none of them could readily form the basis of a platform for the development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

Finance Watch: OrbiMed’s New $1.86bn Fund Offers Financial Alternatives In Tough Market

 
• By 

Public Company Edition: OrbiMed partners Carter Neild and Matthew Rizzo spoke with Scrip about the firm’s fifth royalty and credit fund. Also, Ligand sold $400m worth of notes, BridgeBio’s oncology spinout went public via SPAC merger and raised $261m and Assembly raised $175m.

Asia Deal Watch: Lupin Picks Sandoz To Market Lucentis Biosimilar In Parts Of EU And Asia

Also deals involving Xspray/Handa, Fosun/Expedition, Kaken/Astria, Orchid/Allecra, Sanofi/Visirna, KKR/Healthcare Royalty Partners, Viridian/Kissei, Sandoz/Evotec, Dx&Vx, Dr. Falk/Allianthera, Madrigal/CSPC and Lilly/LTZ.